The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Incretin hormones and type 2 diabetes
Open accessAbstract
A bstract: Incretin hormones (glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1]) play a role in the pathophysiology of type 2 diabetes. Along with their derivatives they have shown therapeutic success in type 2 diabetes, with the potential for further improvements in glycaemic, cardiorenal and body weight-related outcomes. In type 2 diabetes, the incretin effect (greater insulin secretory response after oral glucose than with ‘isoglycaemic’ i.v. glucose, i.e. with an identical glycaemic stimulus) is markedly reduced or absent. This appears to be because of a reduced ability of GIP to stimulate insulin secretion, related either to an overall impairment of beta cell function or to specific defects in the GIP signalling pathway. It is likely that a reduced incretin effect impacts on postprandial glycaemic excursions and, thus, may play a role in the deterioration of glycaemic control. In contrast, the insulinotropic potency of GLP-1 appears to be much less impaired, such that exogenous GLP-1 can stimulate insulin secretion, suppress glucagon secretion and reduce plasma glucose concentrations in the fasting and postprandial states. This has led to the development of incretin-based glucose-lowering medications (selective GLP-1 receptor agonists or, more recently, co-agonists, e.g. that stimulate GIP and GLP-1 receptors). Tirzepatide (a GIP/GLP-1 receptor co-agonist), for example, reduces HbA 1c and body weight in individuals with type 2 diabetes more effectively than selective GLP-1 receptor agonists (e.g. semaglutide). The mechanisms by which GIP receptor agonism may contribute to better glycaemic control and weight loss after long-term exposure to tirzepatide are a matter of active research and may change the pessimistic view that developed after the disappointing lack of insulinotropic activity in people with type 2 diabetes when exposed to GIP in short-term experiments. Future medications that stimulate incretin hormone and other receptors simultaneously may have the potential to further increase the ability to control plasma glucose concentrations and induce weight loss. Graphical Abstract
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Reduced incretin effect in type 2 diabetes. The incretin effect was quantified in individuals with type 2 diabetes (b, e, h, l) and in age- and weight-matched healthy individuals (a, d, g, k) by administering oral glucose (50 g) or an i.v. glucose infusion (a, b), aiming for a matched (‘isoglycaemic’) glycaemic excursion (d–f) to provide the same degree of hyperglycaemia as the stimulus for insulin secretion. With oral glucose, incretin hormones are released from the gut (not shown) and augment the insulin secretory response (g–i) and C-peptide levels (j–l). The difference in insulin secretory response between oral glucose and isoglycaemic i.v. glucose stimulation is the incretin effect, usually expressed as a percentage of the insulin secretory response after oral glucose (c). This measure of the incretin effect is greatly reduced in patients with type 2 diabetes, whether calculated from insulin or C-peptide responses (c). p<0.05; n.s., not significant. Data from [2, 15]. (a, b, d, e, g, h, k, l) adapted from [2] with permission from Springer Nature](https://figures.cochat.ai/paper-figures/140dc4577e064f02b61be78930af3e9d/incretin-hormones-and-type-2-diabetes-figure-1.jpg)
![Fig. 2 Secretion of GLP-1 (a–c) and GIP (d–g) in individuals with type 2 diabetes relative to healthy individuals. (a) Absence of a significant difference in GLP-1total plasma responses following nutrient intake (oral glucose, liquid or solid meals) between individuals with type 2 diabetes and healthy individuals (meta-analysis by Calanna et al [8]). (b) Lack of significant differences in GLP-1total plasma responses following an oral glucose load across categories of glucose tolerance (including screen-detected type 2 diabetes) in women and men [13]. Differences between women and men were not significant for any of the subcategories based on glucose tolerance status. (c) Higher GLP-1total plasma responses following an oral glucose load in women (n=683) than in men (n=779) across all categories of glucose tolerance combined [13]. (d) Absence of a significant difference in GIPtotal plasma responses following nutrient intake (oral glucose, liquid or solid meals) between individuals with type 2 diabetes and healthy individuals (meta-analysis by Calanna et al [9]). (e–g) Subgroup analyses (meta-regression analysis) indicating (non-significant trends for) relatively higher GIPtotal plasma responses following nutrient intake (oral glucose, liquid or solid meals) in individuals with type 2 diabetes vs healthy individuals in the presence of a higher BMI (≥30 kg/m2; e), lower age (≤60 years; f) and lower HbA1c level (≤53 mmol/mol [≤7.0%]); g) [9]. Incretin hormone secretion was systematically assessed measuring total GIP and GLP-1 concentrations (intact GIP and GLP-1 plus metabolites generated by proteolytic degradation). ***p<0.001. AUCt, AUC above a concentration of 0; GLP-1total/GIPtotal, GLP-1/GIP levels including breakdown products recognised in the assay; T2DM, type 2 diabetes](https://figures.cochat.ai/paper-figures/78d8e7675e6746abb52841f92fd0b06c/incretin-hormones-and-type-2-diabetes-figure-2.jpg)
![Fig. 3 Comparison of insulinotropic effects (integrated incremental insulin responses [iAUC]) of GIP (orange) and GLP-1 (green) in participants with type 2 diabetes and healthy control participants, whose mean values were taken as 100% (blue line). For details of the experimental conditions and characteristics of participants, see ESM Table 2. (a) Exogenous GIP and GLP-1 at 0.8 and 2.4 vs 0.4 and 1.2 pmol kg−1 min−1, respectively, for 1 h each during hyperglycaemic clamp experiments aiming at 8.0 mmol/l plasma glucose levels [22]. (b) Exogenous GIP and GLP-1 at 4 and 16 pmol kg−1 min−1 (only in individuals with type 2 diabetes) vs 1.0 pmol kg−1 min−1, respectively, for 2 h each during hyperglycaemic clamp experiments aiming at 15.0 mmol/l plasma glucose levels [23]. (c) Exogenous GIP and GLP-1 at 1.5 vs 0.5 pmol kg−1 min−1, respectively, for 2 h each during hyperglycaemic clamp experiments aiming at 15.0 mmol/l plasma glucose levels, both before and after a 4 week course of intensified insulin therapy to provide near-normoglycaemic plasma glucose concentrations [24]. aResults with a GIP infusion rate of 16 pmol kg−1 min−1 in participants with type 2 diabetes are compared with those obtained with 4 pmol kg−1 min−1 in control participants, as this high dose was not studied in control participants. bGLP-1 was studied in only one healthy control participant, whose value was taken as 100%. *p<0.05 vs healthy control participants. †p<0.05 comparing results before and after intensive insulin treatment in participants with type 2 diabetes. T2D, type 2 diabetes](https://figures.cochat.ai/paper-figures/f83c21ccdb8a4778bee606ff668a81f5/incretin-hormones-and-type-2-diabetes-figure-3.jpg)
![Fig. 4 Plasma glucose at baseline and 6 h after the infusion of exogenous placebo (a), GIP (b), GLP-1 (c) and GIP + GLP-1 (d) in individuals with type 2 diabetes in whom fasting hyperglycaemia was provoked by the omission of the long-acting insulin injection the night before each study (crossover design). Insulin (e) and glucagon (f) responses are also shown as AUCs above (insulin) and below (glucagon) baseline concentrations. Data are redrawn from Mentis et al [41]. Plasma glucose at baseline was not significantly different between the different study days (p=0.59), while plasma glucose concentrations at the end of the experiments differed significantly: placebo vs GIP, p=0.71; placebo vs GLP-1, p<0.001; placebo vs GIP + GLP-1, p<0.001; GIP vs GLP-1, p<0.001; GIP vs GIP + GLP-1, p<0.001; GLP-1 vs GIP + GLP-1, p>0.99. For the other comparisons, *p<0.05. Overall p values are presented for ANOVA comparing all experimental conditions](https://figures.cochat.ai/paper-figures/d9647b9622714646b0717387795a8d2d/incretin-hormones-and-type-2-diabetes-figure-4.jpg)
![Fig. 5 Incretin hormone GLP-1 and its derivatives (GLP-1 receptor agonists) and fasting and postprandial lipids/lipoproteins. (a, d) Effects of GLP-1 receptor agonists on fasting triacylglycerol and HDL-cholesterol concentrations (a) and total and LDL-cholesterol concentrations (d) in individuals with type 2 diabetes (meta-analysis by Song et al [50]). (b, e) Effects of exendin-4 (a GLP-1 receptor agonist), sitagliptin (a DPP-4 inhibitor) and a transgenic GLP-1 receptor knockout (GLP-1 R–/–) on postprandial triacylglycerol (b) and apo B48 (e) levels (relative to untreated control animals) in non-diabetic mice ([52]). (c, f) Effects of GLP-1 receptor agonists (exenatide, left-hand bars [56]; liraglutide, right-hand bars [57], centre bars [58]) on triacylglycerol (c) and apo B48 (f) levels in individuals with type 2 diabetes following a fat-rich meal (relative to placebo treatment). The data displayed in this figure indicate the effects of GLP-1 receptor agonism on fasting lipoprotein particles and, in particular, on the postprandial formation of triacylglycerol-rich lipoproteins (chylomicrons), which is reduced significantly and substantially. *p<0.05 relative to untreated (placebo-treated) control participants](https://figures.cochat.ai/paper-figures/a611211cbdb54fb48daf11c5692cde11/incretin-hormones-and-type-2-diabetes-figure-5.jpg)
![Fig. 6 Quantification of the incretin effect in participants with type 2 diabetes (T2DM) and healthy control participants (HC) based on the measurement of insulin (a–f) and C-peptide (g–l). Data from (a, g) Nauck et al [2] (oral glucose load 50 g); (b, h) Knop et al [71] (oral glucose load 75 g); (c, i) Bagger et al [3] (oral glucose loads of 25, 75 and 125 g); (d, j) Vardarli et al [72] (oral glucose load 75 g; after placebo and vildagliptin treatment); (e, k) Vardarli et al 2014 [73] (oral glucose load 75 g; after placebo and sitagliptin treatment); and (f, l) Laferrere et al [74] (before and after Roux-en-Y gastric bypass in individuals with obesity and type 2 diabetes). A negative value for the incretin effect before Roux-en-Y gastric bypass determined by measuring C-peptide levels is indicated by presenting the results as numbers (mean ± SEM) in panel l. (a–c, g–i) adapted from [4] with permission from Elsevier. *p<0.05](https://figures.cochat.ai/paper-figures/87dceb361fff437eba620f30ec25e11d/incretin-hormones-and-type-2-diabetes-figure-6.jpg)
![Fig. 7 Numbers of publications per year with glucose-dependent insulinotropic polypeptide/gastric inhibitory peptide/GIP and glucagon-like peptide-1/GLP-1 in their title. (a) Publications per calendar year (retrieved from PubMed). (b) Publications per year following the initial discoveries of GIP and GLP-1. The numbers of publications were comparable for the first 9–13 years after the first descriptions, but changed substantially after the characterisation of insulinotropic activity in individuals with type 2 diabetes (decrease after the initial publication showing reduced effectiveness of GIP [21]; increase after the initial publications showing preserved activity of GLP-1 [22, 29]). T2DM, type 2 diabetes](https://figures.cochat.ai/paper-figures/14f6ce1a182b4ab0a48efb914bdbb31c/incretin-hormones-and-type-2-diabetes-figure-7.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The potential value of GIPR agonism was reconsidered when clinical studies with synthetic unimolecular multi-agonist peptides that exert agonism at both GIPR and GLP-1R greatly augmented glucose-lowering and weight-lowering efficacy compared with GLP-1R agonism alone [10,11].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [10]
The cited source says what the claim attributes to it.
In the citing paper
“We are reminded that GLP-1RAs mimic the effects of the incretin hormone GLP-1, notably to potentiate prandial insulin release, reduce glucagon secretion, delay gastric emptying and reduce appetite. These effects combine to promote weight loss and improve glycaemic control in obesity and T2DM [10].”
From Recent advances in peptide-based therapies for obesity and type 2 diabetes (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Kahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · cited 1×
“tirzepatide [84]) or antagonism [100] at the GIP receptor, and of the even more advanced GIP/GLP-1/glucagon receptor triagonists [106], suggest that there is potential for further improvements in the effectiveness (for glycaemic control and weight reduction) of incretin-based medications for the treatment of type 2 di…”
BackgroundGlucagon-like peptide-1 7–36: a physiological incretin in man
Kreymann, B., Ghatei, M. A., Williams, G., & Bloom, S. R. (1987) · The Lancet · doi:10.1016/s0140-6736(87)91194-9 · Cited by 1,928
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“The extraordinary success of incretin-based glucose-lowering medications in type 2 diabetes,, which are mainly based on properties of the incretin hormone glucagon-like peptide-1 (GLP-1) [1], has reinforced interest in the physiology and pathophysiology of incretin hormones more generally.”
BackgroundSelf-citationDeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Reduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“Data from (a, g) Nauck et al [2] (oral glucose load 50 g); (b, h) Knop et al [71] (oral glucose load 75 g); (c, i) Bagger et al [3] (oral glucose loads of 25, 75 and 125 g); (d, j) Vardarli et al [72] (oral glucose load 75 g; after placebo and vildagliptin treatment); (e, k) Vardarli et al 2014 [73] (oral glucose load…”
BackgroundMethodSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Self-citationInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 1×
“Engagement of GIP in a biochemical liaison with GLP-1 seems at first glance counterintuitive, given that the insulinotropic effects and the incretin effect of GIP are severely reduced in people with type 2 diabetes [2, 22] (see earlier), and that GIP receptor-deficient mice are lean and protected from diet-induced obe…”
Background
Research works printed but not linked: 1
- Amgen (2022) AMG 133 is a first-in-class investigational bispecific molecule that activates GLP-1R and inhibits GIPR; phase 1 results showed up to 14.5% reduction in body weight at the highest dose after 12 weeks. https://www.amgen.com/newsroom/press-releases/2022/12/amgen-presents-new-amg-133-phase-1-clinical-data-at-wcirdc-2022
Cited by
Unveiling Gestational Diabetes: An Overview of Pathophysiology and Management
Mittal, R., Prasad, K., Lemos, J. R. N., Arevalo, G., & Hirani, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052320 · Cited by 179
“Incretins, including GLP-1 and glucose-dependent insulinotropic polypeptide (GIP), are gut-derived hormones that enhance insulin secretion in response to nutrient intake [211–214].”
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 129
Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents
Su, J., Luo, Y., Hu, S., Tang, L., & Ouyang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713381 · Cited by 127
Unnikrishnan, R., Shaw, J. E., Chan, J. C. N., Wild, S. H., Peters, A. L., Orrange, S., Roden, M., & Mohan, V. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00635-0 · Cited by 76
“…can result from primary intra-islet abnormalities such as altered insulin release per se, dysregulated processing of pro-insulin, pro-islet amyloid polypeptide and proglucagon 59 , impaired suppression of glucagon by insulin and incretins 60 , and variable incretin secretion patterns 61 .”
Targher, G., Mantovani, A., Byrne, C. D., & Tilg, H. (2024) · Gut · doi:10.1136/gutjnl-2024-334023 · Cited by 60
Metadata
- Authors
- Nauck, M. A., & Müller, T. D.
- Affiliations
- Universitätsmedizin Greifswald (DE)
- Helmholtz Munich (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetologia
- Published
- 2023-07-11
- Volume
- 66
- Issue
- 10
- Pages
- 1780-1795
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC10474001
- OpenAlex
- W4383740618
- Cited by
- 190
- References
- 106
- Citations by year
- 2026: 63 · 2025: 72 · 2024: 48 · 2023: 7
- FWCI
- 6.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dokumentenrepositorium der RUB (Ruhr University Bochum) (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Universitätsklinikum der Ruhr-Universität Bochum
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- incretins, type 2 diabetes, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin effect, beta-cell function, GLP-1 receptor agonists, tirzepatide, insulin secretion, glucagon suppression, weight loss, HbA1c
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Glucose, Humans, Insulin, Weight Loss, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incretin hormones and type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-023-05956-x
- The paper
- Nauck, M. A., & Müller, T. D. (2023). Incretin hormones and type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-023-05956-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.